VKTX

24.7704.14%
LM

Lawson MacArtney

Independent Chairman

Dr. Lawson MacArtney, B.V.M.S., D.V.M., Ph.D., is Independent Director of Exeliom Biosciences. Dr. MacArtney has been the Chairman of Viking Therapeutics, Inc., since June 4, 2015 and has been Director since May 2014. Dr. MacArtney is also a strategic adviser to several investment and private equity groups in both Europe and USA. He served as the Chief Executive Officer and President at Ambrx, Inc. from February 2013 to June 2015. Dr. MacArtney served as Senior Vice President of Emerging Business Unit at Shire plc (Shire AG) from February 2011 to 2013 and was accountable for discovery initiatives through Phase III development of Shire's Specialty Pharmaceutical portfolio. He was successful in expanding and diversifying the pipeline of the Specialty Division through in-house discovery and extensive partnering activities. Before joining Shire in 2011, he was with GlaxoSmithKline (GSK) from 1999 to 2011, where he served as Senior Vice President of Global Product Strategy and Project/Portfolio Management from 2007 to 2011. He served as Senior Vice President, Cardiovascular and Metabolic Medicine Development Center from 2004 to 2007 and as Vice President, Global Head of Cardiovascular, Metabolic and Urology Therapeutic Areas from 1999 to 2004 at GlaxoSmithKline (GSK). Throughout his time at GSK, Dr. MacArtney held leadership roles in the Cardiopulmonary Therapeutic Area, from Project Leader to Global Head for Cardiovascular, Metabolic and Urology. He worked at Ribozyme Pharmaceuticals, AstraMerck and Astra Pharmaceuticals in leadership roles in operations, marketing, sales and customer service from 1998 to 1999. He is a veterinarian, with experience in a range of senior roles in pharmaceutical R&D, sales and marketing, as well as spending several years in veterinary practices. He has global drug development and commercialization experience. He has been an Independent Non-Executive Director at Dechra Pharmaceuticals plc since December 1, 2016 and serves as its Senior Independent Director since March 01, 2022 and on the Supervisory Board of the Netherlands Translational Research Centre. From January 2017 to June 2017, Dr. Macartney served as CEO of Scout Bio Inc. He served as a Director of Ambrx, Inc. since January 7, 2013 until June 2015. He served as Executive Director of Commercial Operations at AstraMerck, Inc from 1996 to 1998. Dr. MacArtney is trained as a Veterinarian and in Diagnostic Pathology. He is a Member of the Royal College of Veterinary Surgeons and a Fellow of the Royal College of Pathologists. He was also a Royal Society Research Fellow of Glasgow University Veterinary School in Scotland. Dr. MacArtney holds B.V.M.S. (equivalent to a D.V.M.). Dr. Macartney received his Ph.D. from Glasgow University in Scotland in 1982.

Positions